Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2026Health Science ReportsOpen Access

Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MJMajid JafariMPMohammad Yazdan PanahSVSaeed Vaheb

Discussion

Loading...

Member takes

Overview

Longitudinal study evaluates ocrelizumab's impact on disease activity and psychological health in MS patients, suggesting potential as a first-line therapy.

Key Points

  • To evaluate the long-term clinical and psychological efficacy and safety of ocrelizumab in people with multiple sclerosis compared to other therapies.
  • Longitudinal study conducted from January 2022 to February 2024
  • Included 51 people with multiple sclerosis, some DMT-naïve and others on existing therapies
  • Evaluated clinical outcomes (EDSS, ARR, T25FW, 9-HPT) and psychological measures (anxiety, depression, fatigue) at three time points (T0, T1, T2)
  • Adverse events were tracked via chart reviews and patient self-reports
  • ARR significantly decreased at T1 and T2 for patients on ocrelizumab
  • Improvements noted in 9-HPT and T25FW at T1
  • Psychological measures including depression and fatigue improved at both T1 and T2
  • First-line therapy patients experienced greater reductions in clinical outcomes
  • Most frequent adverse events were respiratory infections and infusion-related reactions, with no serious infections reported

Cite This Study

Jafari et al. (2026) studied this question.

synapsesocial.com/papers/69c37be2b34aaaeb1a67eb36https://doi.org/10.1002/hsr2.72142
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 Year2026
  2. 2Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis2024 · 4 citations
  3. 3Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study2024 · 3 citations
  4. 4Efficacy and safety of Ocrelizumab in comparison to placebo for multiple sclerosis: A systematic review and meta-analysis2025
  5. 5CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany2025 · 4 citations